<SEC-DOCUMENT>0001213900-26-086150.txt : 20260806
<SEC-HEADER>0001213900-26-086150.hdr.sgml : 20260806
<ACCEPTANCE-DATETIME>20260806161301
ACCESSION NUMBER:		0001213900-26-086150
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20260731
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260806
DATE AS OF CHANGE:		20260806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OS Therapies Inc
		CENTRAL INDEX KEY:			0001795091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				825118368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42195
		FILM NUMBER:		261249196

	BUSINESS ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		410-297-7793

	MAIL ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OS THERAPIES Inc
		DATE OF NAME CHANGE:	20191125
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0300848-8k_ostherapies.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-roles="http://fasb.org/us-roles/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:OSTX="http://ostherapies.com/20260731">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02F_US%2DGAAP%2D2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_OSTX_ostherapies.com_20260731 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20260731_20260731 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001795091 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000004" name="dei:EntityCentralIndexKey">0001795091</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ostx-20260731.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-07-31</xbrli:startDate>
        <xbrli:endDate>2026-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_c20260731__20260731_zaROyFeqoUS"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span style="text-decoration: underline"><span id="xdx_901_edei--DocumentPeriodEndDate_c20260731__20260731_zRp1vC00NeBa"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">July 31, 2026</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20260731__20260731_zhRxLEq1BlMi"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000011" name="dei:EntityRegistrantName">OS THERAPIES
INCORPORATED</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20260731__20260731_zMDKGImqvjRd"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span id="xdx_909_edei--EntityFileNumber_c20260731__20260731_zq99FcCxTKth"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000013" name="dei:EntityFileNumber">001-42195</ix:nonNumeric></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20260731__20260731_zSkNcPPPtl7d"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000014" name="dei:EntityTaxIdentificationNumber">82-5118368</ix:nonNumeric></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center">(State or other jurisdiction<br/>
of incorporation)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">(IRS Employer<br/>
Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20260731__20260731_zuixrEw6zmth"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000015" name="dei:EntityAddressAddressLine1">115 Pullman Crossing Road</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20260731__20260731_zrsADRK0ntdf"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 103</ix:nonNumeric></span><br/>
<span id="xdx_904_edei--EntityAddressCityOrTown_c20260731__20260731_zc4BQWojOkZ7"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000017" name="dei:EntityAddressCityOrTown">Grasonville</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20260731__20260731_zcAhvKX2DgEd"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span id="xdx_902_edei--EntityAddressPostalZipCode_c20260731__20260731_zynozrh5uoU2"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000019" name="dei:EntityAddressPostalZipCode">21638</ix:nonNumeric></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of Principal Executive Offices)</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <span style="text-decoration: underline">(<span id="xdx_904_edei--CityAreaCode_c20260731__20260731_z3WrVdjVtkp9"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000020" name="dei:CityAreaCode">410</ix:nonNumeric></span>)</span> <span id="xdx_90C_edei--LocalPhoneNumber_c20260731__20260731_z6f4I1FHwXH6"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000021" name="dei:LocalPhoneNumber">297-7793</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--WrittenCommunications_c20260731__20260731_zUPniFaZFGH8"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--SolicitingMaterial_c20260731__20260731_zck7VTvejbNg"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20260731__20260731_zVERQUODaYB2"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20260731__20260731_zfGmx9VEGSMc"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><b>Title of Each Class</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><b>Trading Symbol(s)</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><b>Name of Each Exchange on Which Registered</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_904_edei--Security12bTitle_c20260731__20260731_zlg1Ljyy7Qs4"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_edei--TradingSymbol_c20260731__20260731_z0TqJ5lF2ad4"><ix:nonNumeric contextRef="AsOf2026-07-31" id="Fact000027" name="dei:TradingSymbol">OSTX</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_edei--SecurityExchangeName_c20260731__20260731_zxPnybXnj9f3"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20260731__20260731_z46TelE7Tv8l"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--EntityExTransitionPeriod_c20260731__20260731_zonHXxTsd2e9"><ix:nonNumeric contextRef="AsOf2026-07-31" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT ON FORM 8-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>July 31, 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01. Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leonite 2026 Secured Financing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed, on
June 30, 2026, OS Therapies Incorporated (the &#8220;Company&#8221;), together with its wholly owned subsidiaries, entered into a securities
purchase agreement (the &#8220;Leonite SPA&#8221;) with Leonite Fund I, LP (&#8220;Leonite&#8221;) and related transaction documents,
pursuant to which the Company issued and sold to Leonite, in a private placement (the &#8220;Leonite Private Placement&#8221;), a senior
secured convertible promissory note in an aggregate principal amount of up to $10,000,000 (the &#8220;Leonite Note&#8221;). As additional
consideration for Leonite&#8217;s purchase of the Note, the Company issued to Leonite (i) 275,000 shares of the Company&#8217;s common
stock (the &#8220;Leonite Commitment Shares&#8221;) and (ii) a five-year warrant (the &#8220;Leonite Warrant&#8221;) to purchase up to
1,750,000 shares of the Company&#8217;s common stock at an initial exercise price of $2.85 per share, subject to adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Leonite SPA,
Leonite agreed to purchase the Leonite Note in one or more tranches, in an aggregate principal amount of up to $10,000,000. Each funded
tranche was subject to an original issue discount of 7.5%, which was included in the principal amount of the Leonite Note and was earned
only upon the funding of such tranche. On July 2, 2026, Leonite funded the initial tranche in the principal amount of $1,600,000 (less
$35,000 retained by Leonite for legal fees and expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Leonite Note was secured
by a continuing first-priority security interest in substantially all of the Company&#8217;s and its subsidiaries&#8217; existing and
after-acquired assets, subject to certain exclusions, including intellectual property assets. Notwithstanding such exclusions, the collateral
included accounts, payment intangibles and other rights to payment arising from the sale, license or other disposition of intellectual
property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leonite Settlement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 31, 2026, the Company,
together with its wholly owned subsidiaries, entered into a settlement agreement and mutual release with Leonite (the &#8220;Leonite Settlement
Agreement&#8221;), pursuant to which the Company agreed to pay Leonite $1,900,000 in cash (the &#8220;Leonite Settlement Payment&#8221;)
and issue to Leonite 500,000 shares of the Company&#8217;s common stock (the &#8220;Leonite Settlement Shares&#8221;) on or before August
7, 2026 (the &#8220;Outside Date&#8221;) in full and complete satisfaction of all amounts outstanding under the Leonite Note and the other
transaction documents related to the Leonite Private Placement (the &#8220;Leonite Settlement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Leonite Settlement Agreement
requires that the Leonite Settlement Shares be issued pursuant to the Company&#8217;s effective shelf registration statement on Form S-3
(File No. 333-289443) and a prospectus supplement filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), on or prior to the date of issuance of the Leonite Settlement Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the Leonite
Settlement will occur upon Leonite&#8217;s receipt of both the Leonite Settlement Payment and the Leonite Settlement Shares (the &#8220;Settlement
Closing&#8221;), which the Company expects to occur on or before the Outside Date. Effective upon the Settlement Closing: (i) the Leonite
Note and all amounts outstanding thereunder will be deemed fully paid, satisfied, discharged and cancelled, and all conversion rights
thereunder will terminate; (ii) the Leonite Warrant will be terminated and cancelled in its entirety, unexercised; (iii) the Leonite Commitment
Shares will be surrendered by Leonite to the Company for cancellation; (iv) the Leonite SPA, the related security agreement and all other
transaction documents entered into in connection with the Leonite Private Placement will terminate and cease to be of any further force
or effect, including all rights of Leonite under the participation rights, rights of first refusal, future financing rights, disclosure
rights relating to future financings, rollover rights and registration rights provisions of the Leonite SPA; and (v) all security interests,
liens, pledges and other collateral granted to or for the benefit of Leonite will be automatically, unconditionally and irrevocably released,
terminated and discharged, and all assets assigned to Leonite by OS Therapies UK Ltd, our wholly owned subsidiary (&#8220;OSUK&#8221;),
including value added tax repayments and research and development tax relief claims, will revert to OSUK free and clear of any claim or
lien of Leonite.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Leonite Settlement
Agreement, effective upon the Settlement Closing, the parties agreed to exchange unconditional mutual releases of all claims, counterclaims,
demands, actions and causes of action of every kind and nature, whether known or unknown, suspected or unsuspected, arising out of, relating
to or in connection with any act, omission, event or occurrence existing at or prior to the Settlement Closing, including the transaction
documents entered into in connection with the Leonite Private Placement, the transactions contemplated thereby and the disputes between
the parties, subject to a customary carve-out preserving the parties&#8217; respective rights and obligations under the Leonite Settlement
Agreement. Each party also agreed to waive, to the fullest extent permitted by law, the provisions, rights and benefits of any statute,
rule, doctrine or common law principle that would limit the scope or effectiveness of a general release with respect to unknown or unsuspected
claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Settlement Closing
has not occurred on or before the Outside Date (other than due to Leonite&#8217;s willful refusal to accept a proper tender), the Company
has a five-business day cure period. If the Settlement Closing has not occurred by the end of the cure period, Leonite will have the right
to terminate the Leonite Settlement Agreement, in which case the Leonite Note, the Leonite Warrant and all other transaction documents
entered into in connection with the Leonite Private Placement would continue in full force and effect as if the Leonite Settlement Agreement
had never been executed, and all rights, remedies, claims, defaults and events of default of Leonite thereunder would be expressly reserved
and preserved. Any portion of the Leonite Settlement Payment received by Leonite prior to such termination would be retained by Leonite
and applied against amounts outstanding under the Leonite Note. In such event, the Company would remain subject to all of its obligations
under the Leonite Note, including payment of up to $10,000,000 in principal, interest at 9% per annum and other amounts, and the Company&#8217;s
assets would remain subject to Leonite&#8217;s first-priority security interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2026, in connection
with the Leonite Settlement, the Company issued to an accredited investor a bridge convertible promissory note in the principal amount
of $2,200,000 (the &#8220;Bridge Note&#8221;) for a purchase price of $2,190,000. The Bridge Note does not bear interest and matures on
September 1, 2026, unless earlier converted by the holder. The Company may not prepay the Bridge Note without the prior written consent
of the holder. Upon the initial closing of a private offering by the Company of original issue discount promissory notes in an aggregate
principal amount of up to $10,000,000, the outstanding principal amount of the Bridge Note will automatically convert into the securities
issued in such offering on the same terms as the other purchasers in the offering. The Bridge Note also contains customary events of default,
upon the occurrence of which the holder may declare the outstanding principal amount of the Bridge Note to be immediately due and payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 3, 2026, in accordance
with the terms of the Bridge Note, the Company used the proceeds of the Bridge Note to fund the Leonite Settlement Payment. The remaining
proceeds from the Bridge Note will be used for general working capital and ordinary course operating expenses of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Leonite Settlement Shares
are being offered pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company
with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on August 8, 2025 and declared effective by the SEC on August 25,
2025, and the prospectus supplement dated August 6, 2026 filed by the Company with the SEC on August 6, 2026. The Company expects to issue
to Leonite the Leonite Settlement Shares on or about August 6, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
of the Leonite Settlement Agreement and Bridge Note do not purport to be complete and are qualified in their entirety by reference to
the full text of the Leonite Settlement Agreement and the form of Bridge Note, copies of which are filed as Exhibits 10.1 and 4.1, respectively,
to this Current Report on Form 8-K and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Leonite Settlement Agreement
contains customary representations, warranties and covenants by the Company which were made only for the purposes of the Leonite Settlement
Agreement and as of specific dates, were solely for the benefit of the parties to the Leonite Settlement Agreement and may be subject
to limitations agreed upon by the contracting parties. Accordingly, the Leonite Settlement Agreement is incorporated herein by reference
only to provide investors with information regarding the terms of the Leonite Settlement Agreement and not to provide investors with any
other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s
reports and other filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The legal opinion, including
the related consent, of Olshan Frome Wolosky LLP relating to the issuance and sale of the Settlement Shares is filed as Exhibit 5.1 to
this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Current Report on Form
8-K does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2.03. Creation of a Direct Financial Obligation
or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set forth
under Item 1.01 of this Current Report on Form 8-K with respect to the Bridge Note is hereby incorporated by reference into this Item
2.03.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02. Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information contained
in Item 1.01 of this Current Report on Form 8-K with respect to the Bridge Note is hereby incorporated by reference into this Item 3.02.
The Bridge Note was offered and sold by the Company in reliance upon an exemption from the registration requirements of the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), afforded by Section 4(a)(2) thereof and/or Regulation D promulgated thereunder.
The purchaser of the Bridge Note represented that it is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities
Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>(d) Exhibits.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: justify"><b>Exhibit<br/>
Number &#160;</b></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: justify"><b>Description &#160;</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">4.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="text-decoration: none"><a href="ea030084801ex4-1.htm">Form of Bridge Convertible Promissory Note.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">5.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="text-decoration: none"><a href="ea030084801ex5-1.htm">Opinion of Olshan Frome Wolosky LLP.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.1*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="text-decoration: none"><a href="ea030084801ex10-1.htm">Settlement Agreement and Mutual Release, dated as of July 31, 2026, among OS Therapies Incorporated, OS Animal Health Inc., OS Therapies UK LTD and Leonite Fund I, LP.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">23.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="text-decoration: none"><a href="ea030084801ex5-1.htm">Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">104</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">*</td>
    <td style="text-align: justify">Pursuant to Item 601(a)(5) of Regulation S-K, certain schedules and exhibits have been omitted. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon its request.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><b>OS THERAPIES INCORPORATED</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Dated: August 6, 2026</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">/s/ Paul A. Romness, MPH</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 5%">Name:</td>
    <td style="width: 32%">Paul A. Romness, MPH</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:</td>
    <td>President and Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLMWnLJHh4o4RYaIr8VFKW7NSOucn+RfWjfEEAjJvSdXiJFY08pUyHBeFDkcsW4q7REKvCKjvWBwZJttCmEWeDPOs7a+X39gRoHBwCTxVId772yNwzIFOR/L6VglIGepUnDYieirZ2SvpkTrja5A2xIOTA0b9Jpfw4ej7shS/eqTTsjOkE1hEstBfoOSEwV7avWT+O4gzzMRjfqKxJrp0QTXsvNovyQsK6xDnBvof0cf0I9KZA== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea030084801ex4-1.htm
<DESCRIPTION>FORM OF BRIDGE CONVERTIBLE PROMISSORY NOTE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>BRIDGE CONVERTIBLE PROMISSORY
NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Purchase Price</B>: $2,190,000<BR>
<B>Principal Amount</B>: $2,200,000<BR>
<B>Date of Issuance</B>: August 2, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">FOR VALUE RECEIVED, <B>OS Therapies
Incorporated</B>, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), hereby promises to pay to <B>_________</B> (the &ldquo;<B>Holder</B>&rdquo;),
the principal sum of $2,200,000 (the &ldquo;<B>Principal Amount</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD><B>Non-Interest Bearing.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Note shall be non-interest
bearing, and no interest shall accrue on the outstanding Principal Amount hereof, whether before or after the Maturity Date. The Holder
acknowledges that this Note is being issued at an original issue discount and that the Holder&rsquo;s economic return is reflected in
the original issue discount and the automatic conversion provisions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD><B>Maturity.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Unless earlier converted pursuant
to Section 3 below, the outstanding Principal Amount of this Note shall become due and payable in full on September 1, 2026 (the &ldquo;<B>Maturity
Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>3.</B></TD><TD><B>Automatic Conversion.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Upon the initial closing of
the Company&rsquo;s private offering of original issue discount promissory notes in the principal amount of up to $10 million, issued
together with closing shares and warrants and approved by the Company&rsquo;s Board of Directors following the date hereof (the &ldquo;<B>Qualified
OID Financing</B>&rdquo;), this Note shall automatically convert, without any further action by the Company or the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Upon such automatic conversion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the outstanding Principal Amount of this Note shall be deemed paid and satisfied in full;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">solely for purposes of determining the securities issuable to the Holder in the Qualified OID Financing,
the Holder shall be deemed to have subscribed for securities in the Qualified OID Financing using a subscription amount equal to the outstanding
Principal Amount of this Note; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">in exchange for the cancellation of this Note, the Holder shall receive the same form of original issue
discount promissory notes, closing shares and warrants issued to purchasers in the Qualified OID Financing, with the principal amount
of such notes, closing shares, warrant coverage and all other terms determined in the same manner as if the Holder had subscribed for
securities in the Qualified OID Financing using the outstanding Principal Amount of this Note as the subscription amount</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Following the occurrence of
the Qualified OID Financing, this Note shall automatically terminate and be cancelled, and the Holder shall thereafter have only those
rights set forth in the transaction documents that are issued in the Qualified OID Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>4.</B></TD><TD><B>Prepayment.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Note may not be prepaid
by the Company without the prior written consent of the Holder prior to the occurrence of the Qualified OID Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>5.</B></TD><TD><B>Use of Proceeds.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company shall use the proceeds
from the issuance of this Bridge Note to fund the Settlement Payment to Leonite Fund I, LP, as defined in that certain Settlement Agreement
and Mutual Release dated July 31, 2026 and for general working capital and ordinary course operating expenses of the Company, including
the funding of current payroll incurred in the ordinary course of business and consistent with past practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>6.</B></TD><TD><B>Events of Default.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Each of the following shall
constitute an Event of Default:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the Company&rsquo;s failure to pay the outstanding Principal Amount of this Note on the Maturity Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">the commencement by or against the Company of any bankruptcy, insolvency, receivership or similar proceeding
that is not dismissed within sixty (60) days; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">the dissolution or liquidation of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Upon the occurrence of an Event
of Default, the Holder may declare the outstanding Principal Amount immediately due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>7.</B></TD><TD><B>Accredited Investor Representations.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Holder represents and warrants
to the Company that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the Holder is an &ldquo;accredited investor,&rdquo; as such term is defined in Rule 501(a) promulgated
under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">the Holder is acquiring this Note for its own account, for investment purposes only, and not with a view
to, or for resale in connection with, any distribution thereof in violation of the Securities Act or applicable state securities laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">the Holder recognizes that an investment in the Note involves a high degree of risk, including the possible
loss of the Holder&rsquo;s entire investment, has carefully considered and understands the risks associated with an investment in the
Company and the Note, and is able to bear the economic risk of such investment for an indefinite period of time and to withstand the complete
loss of such investment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">the Holder has such knowledge and experience in financial and business matters that it is capable of evaluating
the merits and risks of an investment in the Note and of protecting its own interests in connection therewith;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">the Holder acknowledges that this Note has not been registered under the Securities Act or any applicable
state securities laws and may not be offered, sold, assigned, pledged or otherwise transferred except pursuant to an effective registration
statement or an available exemption from the registration requirements of the Securities Act and applicable state securities laws; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">the Holder has had the opportunity to ask questions of, and receive answers from, the Company regarding
the terms of this Note and the Company&rsquo;s business, financial condition and operations, and has received all information the Holder
considers necessary to make an informed investment decision.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>8.</B></TD><TD><B>Miscellaneous.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Note may be amended or
modified only by a written instrument executed by the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company and the Holder hereby
waive presentment, demand, notice of dishonor, protest and notice of protest with respect to this Note and any obligation hereunder, except
as expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any waiver of any provision
of this Note or any default hereunder shall be effective only if made in writing and signed by the party granting such waiver. No failure
or delay by either party in exercising any right, power or remedy under this Note shall operate as a waiver thereof, nor shall any single
or partial exercise of any right, power or remedy preclude any other or further exercise thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">All notices, requests, demands
and other communications required or permitted to be given under this Note shall be in writing and shall be deemed given when delivered
personally, sent by nationally recognized overnight courier, or sent by electronic mail (with confirmation of transmission), to the addresses
or email addresses of the parties set forth in the Company&rsquo;s records or on the signature page hereto, or to such other address or
email address as either party may designate by written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Note shall be binding upon
and inure to the benefit of the Company and the Holder and their respective successors and permitted assigns. Neither the Company nor
the Holder may assign, delegate, transfer or otherwise dispose of any of its rights or obligations under this Note without the prior written
consent of the other party; provided, however, that the Holder may assign or transfer this Note without the Company&rsquo;s consent to
an affiliate of the Holder or in connection with a transfer of this Note that is otherwise permitted under applicable securities laws,
provided that such assignee agrees in writing to be bound by the terms of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If any provision of this Note
is determined to be invalid, illegal or unenforceable, the remaining provisions of this Note shall remain in full force and effect, and
such provision shall be modified to the minimum extent necessary to make it valid and enforceable while preserving the intent of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Note constitutes the entire
agreement of the Company and the Holder with respect to the subject matter hereof and supersedes all prior discussions, negotiations and
understandings, whether oral or written, relating to such subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Note may be executed in
counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Electronic
signatures and signatures delivered by electronic transmission shall be deemed effective as original signatures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Note shall be governed
by and construed in accordance with the internal laws of the State of New York, without giving effect to any conflict of laws principles.
The Company and the Holder hereby irrevocably submit to the exclusive jurisdiction of the state and federal courts located in the Borough
of Manhattan, City of New York, with respect to any dispute arising out of or relating to this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Note to be signed in its name by its duly authorized officer as of the Issue Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><B>OS THERAPIES INCORPORATED</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Date:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>HOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">By executing this Note, the
undersigned Holder hereby acknowledges and agrees to the terms of this Note and represents and warrants to the Company that each of the
representations and warranties set forth in Section 7 of this Note is true and correct as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 32%"></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Date:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea030084801ex5-1.htm
<DESCRIPTION>OPINION OF OLSHAN FROME WOLOSKY LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ea030084801_ex5-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">August 6, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OS Therapies Incorporated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">115 Pullman Crossing Road, Suite 103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grasonville, Maryland 21638</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are acting as legal counsel
to OS Therapies Incorporated, a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the offer and sale by the Company
of 500,000 shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share, pursuant to the Company&rsquo;s
Registration Statement on Form S-3 (Registration No. 333-289443) (the &ldquo;Registration Statement&rdquo;), filed by the Company with
the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;),
on August 8, 2025 and declared effective by the Commission on August 25, 2025, including the base prospectus, dated August 25, 2025, constituting
a part of the Registration Statement, filed by the Company with the Commission pursuant to Rule 424(b)(3) under the Act on August 25,
2025 (the &ldquo;Base Prospectus&rdquo;), as supplemented by the prospectus supplement, dated August 6, 2026, filed by the Company with
the Commission pursuant to Rule 424(b)(5) under the Act on August 6, 2026 (such prospectus supplement, together with the Base Prospectus,
the &ldquo;Prospectus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion
letter, we have examined (a) the Registration Statement, (b) the Prospectus, (c) the Third Amended and Restated Certificate of Incorporation
of the Company, as amended to date, (d) the Amended and Restated Bylaws of the Company, as amended to date, and (e) certain resolutions
of the Board of Directors of the Company relating to the issuance, sale and registration of the Shares. In addition, we have examined
and relied upon such corporate records of the Company, and have made such examination of law, as we have deemed necessary or appropriate
for purposes of the opinions expressed below. As to certain factual matters, unless otherwise indicated, we have relied, to the extent
we have deemed proper, on certificates of certain officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have assumed for purposes
of rendering the opinions set forth herein, without any verification by us, the genuineness of all signatures, the legal capacity of all
natural persons to execute and deliver documents, the authenticity and completeness of documents submitted to us as originals, the completeness
and conformity with authentic original documents of all documents submitted to us as copies, and that all documents, books and records
made available to us by the Company are accurate and complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon, subject to and
limited by the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and, upon issuance, delivery
and payment therefor in the manner contemplated by the Registration Statement and the Prospectus, will be validly issued, fully paid and
nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ea030084801_ex5-1img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 6, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are members of the Bar
of the State of New York. We do not express any opinion as to the effect of any laws other than the laws of the State of New York and
the General Corporation Law of the State of Delaware, and the federal laws of the United States of America, as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter speaks only at
and as of its date and is based solely on the facts and circumstances known to us at and as of such date. We assume no obligation to revise
or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in fact or law
that may hereafter occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Act with the Commission
as an exhibit to the Current Report on Form 8-K to be filed by the Company in connection with the issuance and sale of the Shares and
to the use of our name in the Prospectus under the caption &ldquo;Legal Matters.&rdquo; In giving such consent, we do not hereby admit
that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><I>/s/ Olshan Frome
                                            Wolosky LLP</I></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OLSHAN FROME WOLOSKY LLP</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ea030084801ex10-1.htm
<DESCRIPTION>SETTLEMENT AGREEMENT AND MUTUAL RELEASE, DATED AS OF JULY 31, 2026, AMONG OS THERAPIES INCORPORATED, OS ANIMAL HEALTH INC., OS THERAPIES UK LTD AND LEONITE FUND I, LP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SETTLEMENT AGREEMENT AND MUTUAL RELEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This SETTLEMENT AGREEMENT
AND MUTUAL RELEASE (this &ldquo;Agreement&rdquo;) is made and entered into as of July 31, 2026 (the &ldquo;Effective Date&rdquo;), by
and among OS Therapies Incorporated, a corporation organized under the laws of the State of Delaware (&ldquo;OSTX&rdquo;), OS Animal Health
Inc., a corporation organized under the laws of the State of Delaware, and OS Therapies UK LTD, a limited company organized under the
laws of the United Kingdom (collectively, jointly and severally, the &ldquo;Company&rdquo;), and Leonite Fund I, LP, a limited partnership
organized under the laws of the State of Delaware (&ldquo;Leonite&rdquo;). The Company and Leonite are each referred to herein as a &ldquo;Party&rdquo;
and collectively as the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">The Company and Leonite are parties to that certain Securities Purchase Agreement, dated as of June 30,
2026 (the &ldquo;Purchase Agreement&rdquo;), pursuant to which the Company issued and sold to Leonite (i) that certain Senior Secured
Convertible Promissory Note, dated June 30, 2026, in the principal amount of up to $10,000,000, funded in one or more tranches and bearing
interest at the rate of nine percent (9%) per annum (the &ldquo;Note&rdquo;), (ii) two hundred seventy-five thousand (275,000) shares
of common stock, par value $0.001 per share, of OSTX (the &ldquo;Common Stock&rdquo;), held by Leonite in restricted form (the &ldquo;Commitment
Shares&rdquo;), and (iii) that certain Common Stock Purchase Warrant, dated June 30, 2026, exercisable for up to one million seven hundred
fifty thousand (1,750,000) shares of Common Stock at an exercise price of $2.85 per share, subject to adjustment as provided therein (the
&ldquo;Warrant&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">The obligations of the Company under the Note are secured pursuant to that certain Pledge and Security
Agreement, dated as of June 30, 2026, by and between the Company and Leonite (the &ldquo;Security Agreement&rdquo;), that certain Assignment
of Assets executed by OS Therapies UK LTD in favor of Leonite (the &ldquo;Assignment of Assets&rdquo;), and the UCC-1 financing statements
and other filings, registrations and instruments executed, filed or recorded in connection therewith (collectively with the Security Agreement
and the Assignment of Assets, the &ldquo;Security Documents&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify">In connection with the foregoing, OSTX and Leonite delivered an irrevocable instruction letter, dated
on or about June 30, 2026, to OSTX&rsquo;s transfer agent (the &ldquo;Transfer Agent&rdquo; and, such letter, the &ldquo;TA Letter&rdquo;),
and OSTX and Leonite entered into that certain letter agreement, dated June 30, 2026, relating to Section 2.2(b)(4) of the Note (the &ldquo;Side
Letter&rdquo;). The Purchase Agreement, the Note, the Warrant, the Security Documents, the TA Letter, the Side Letter and each other agreement,
instrument, certificate and document executed or delivered in connection therewith are referred to herein, collectively, as the &ldquo;Transaction
Documents.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">D.</TD><TD STYLE="text-align: justify">Certain disputes, disagreements and potential claims have arisen or may arise between the Parties arising
out of or relating to the Transaction Documents and the transactions contemplated thereby (collectively, the &ldquo;Disputes&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">E.</TD><TD STYLE="text-align: justify">Without any admission of liability or wrongdoing by any Party, the Parties desire fully and finally to
compromise, resolve and settle the Disputes, to provide for the satisfaction of the Note, the cancellation of the Warrant and the Commitment
Shares, the termination of the Transaction Documents and the release of all security interests thereunder, and to exchange unconditional
mutual releases, in each case upon the terms and subject to the conditions set forth in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants, agreements, releases and payments set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><B>Definitions; Interpretation. </B>Capitalized terms used but not otherwise defined in this Agreement
shall have the meanings ascribed to such terms in the Purchase Agreement or the Note, as applicable. As used herein, &ldquo;Business Day&rdquo;
means any day other than a Saturday, a Sunday or a day on which the NYSE American is closed or on which banking institutions in the State
of New York are authorized or required by law to remain closed. The headings in this Agreement are for convenience of reference only and
shall not affect its interpretation. The word &ldquo;including&rdquo; means &ldquo;including, without limitation.&rdquo; This Agreement
shall be deemed to have been drafted jointly by the Parties, and no rule of construction shall be applied against any Party as the drafter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><B>Settlement Payment. </B>On or before 4:00 p.m. (New York City time) August 7, 2026 (the &ldquo;Outside
Date&rdquo;), the Company shall pay to Leonite the sum of One Million Nine Hundred Thousand Dollars ($1,900,000) (the &ldquo;Settlement
Payment&rdquo;) in cash, in immediately available funds, by wire transfer to the account of Leonite set forth on <U>Exhibit A</U> hereto.
The Settlement Payment shall be paid free and clear of, and without, any setoff, deduction, recoupment, counterclaim or withholding of
any kind. The Parties acknowledge and agree that the Settlement Payment, together with the Settlement Shares (as defined below), constitutes
full and complete satisfaction of all amounts owing under the Note and the other Transaction Documents, including all principal, accrued
and unpaid interest (including any minimum guaranteed interest), original issue discount, fees, premiums, charges, penalties, monitoring
fees, enforcement costs and any other amounts of whatever nature, regardless of whether such amounts have been accelerated. Notwithstanding
anything to the contrary contained in the Note, including (i) any provision thereof restricting, conditioning or imposing any premium
upon prepayment (including the 110% prepayment premium set forth in Section 1.5 thereof), (ii) any notice period required in connection
therewith (including the 30-day and 45-day notice periods set forth in Sections 1.5 and 4.3 thereof), and (iii) any conversion right of
Leonite that would otherwise be triggered by such notice or payment, the Company is authorized and directed to make, and Leonite agrees
to accept, the Settlement Payment in accordance with this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><B>Settlement Shares. </B>On or before the Outside Date, OSTX shall issue and deliver to Leonite five
hundred thousand (500,000) shares of Common Stock (the &ldquo;Settlement Shares&rdquo;). The Settlement Shares shall be (a) issued and
sold pursuant to OSTX&rsquo;s effective shelf registration statement on Form S-3 (File No. 333-289443) (the &ldquo;Registration Statement&rdquo;)
and a prospectus supplement thereto to be filed by OSTX with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) pursuant
to Rule 424(b) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), on or prior to the date of issuance of
the Settlement Shares and in any event within the time required by Rule 424(b); (b) upon issuance, duly authorized, validly issued, fully
paid and nonassessable, free and clear of all liens, claims, encumbrances and rights of third parties, and free of any restrictive legend,
stop transfer order or other restriction on transfer; and (c) delivered by crediting the account of Leonite or its designee with The Depository
Trust Company through its Deposit/Withdrawal at Custodian (DWAC) system in accordance with the delivery instructions set forth on Exhibit
A hereto. OSTX shall take all action necessary to cause the Settlement Shares to be approved for listing on the NYSE American on or prior
to their issuance, including the timely submission of any required additional listing application, and shall pay all fees of the Transfer
Agent, The Depository Trust Company and the NYSE American in connection with the issuance and delivery of the Settlement Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><B>Closing; Time of the Essence. </B>The closing of the settlement contemplated by this Agreement (the
&ldquo;Closing&rdquo;) shall occur automatically upon Leonite&rsquo;s receipt of both (a) the Settlement Payment in accordance with Section
2 and (b) the Settlement Shares in accordance with Section 3. The Parties acknowledge and agree that time is of the essence with respect
to the obligations of the Company under Sections 2 and 3 and that the occurrence of the Closing on or before the Outside Date is a material
inducement to Leonite&rsquo;s entry into this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><B>Effect of the Closing. </B>Effective automatically upon the occurrence of the Closing, and without
the need for any further action by any Party:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">5.1.</TD><TD STYLE="text-align: justify"><B>Satisfaction and Cancellation of the Note. </B>The Note, and all principal, interest, original issue
discount, fees, premiums, charges and other amounts owing thereunder or in respect thereof, shall be deemed fully paid, satisfied, discharged,
terminated and cancelled, and the Company shall have no further obligation, and Leonite shall have no further right, under the Note, including
any right of conversion. Within five (5) Business Days after the Closing, Leonite shall deliver the original Note to the Company marked
&ldquo;cancelled&rdquo; or, if the original cannot be located, a customary lost instrument affidavit in lieu thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">5.2.</TD><TD STYLE="text-align: justify"><B>Cancellation of the Warrant. </B>The Warrant shall be terminated and cancelled in its entirety, unexercised,
and shall be void and of no further force or effect, and Leonite shall have no further right to purchase or acquire any securities of
OSTX thereunder, including any right arising from any adjustment provision thereof. Within five (5) Business Days after the Closing, Leonite
shall deliver the original Warrant to the Company marked &ldquo;cancelled&rdquo; or, if the original cannot be located, a customary lost
instrument affidavit in lieu thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">5.3.</TD><TD STYLE="text-align: justify"><B>Cancellation of the Commitment Shares. </B>Leonite shall surrender the Commitment Shares to OSTX for
cancellation, and OSTX and Leonite shall deliver joint irrevocable instructions to the Transfer Agent directing the Transfer Agent to
cancel the Commitment Shares and to restore such shares to the status of authorized but unissued shares of Common Stock. From and after
the Closing, Leonite shall have no right, title or interest in or to the Commitment Shares, and the Commitment Shares shall be deemed
cancelled for all purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">5.4.</TD><TD STYLE="text-align: justify"><B>Termination of the Transaction Documents; Release of Collateral. </B>Each of the Transaction Documents,
including the Purchase Agreement, the Note, the Warrant, the Security Agreement, the Assignment of Assets, the other Security Documents,
the TA Letter and the Side Letter, shall terminate and be of no further force or effect, and, notwithstanding any provision of any Transaction
Document purporting to survive its termination, from and after the Closing the rights and obligations of the Parties with respect to the
subject matter of the Transaction Documents shall be governed exclusively by this Agreement. Without limiting the generality of the foregoing,
all rights of Leonite under Sections 4.12 (Right of Participation), 4.13 (Right of First Refusal), 4.14 (Terms of Future Financings),
4.15 (Disclosure of Future Financings), 4.16 (Rollover Rights) and 4.17 (Registration Rights) of the Purchase Agreement, and all analogous
rights under any other Transaction Document, shall terminate and be of no further force or effect. All security interests, liens, pledges,
charges, assignments and other collateral or credit support granted to or for the benefit of Leonite under the Security Documents or any
other Transaction Document shall be automatically, unconditionally and irrevocably released, terminated and discharged. The Assignment
of Assets shall terminate and all right, title and interest in and to the Assigned Assets (as defined therein), including all VAT repayments,
R&amp;D tax relief claims and other amounts assigned thereunder, shall automatically revert to and be vested in OS Therapies UK LTD, free
and clear of any claim, lien or interest of Leonite. Leonite hereby authorizes the Company, effective upon the Closing, to file UCC-3
termination statements with respect to all UCC-1 financing statements filed against the Company or any of its subsidiaries in favor of
Leonite, and Leonite shall, within ten (10) Business Days after the Closing (or, if earlier, within five (5) Business Days after the Company&rsquo;s
written request therefor), promptly execute and deliver such releases, discharges, terminations and other instruments as are reasonably
necessary to evidence the release of such security interests, including without limitation any necessary filings, deregistrations or releases
required under the laws of any applicable jurisdiction (including the United Kingdom), in each case at the sole expense of the Company.
Nothing in this Section 5.4 shall terminate, release or impair this Agreement, including the releases set forth in Section 6 and the indemnification
set forth in Section 7.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><B>Mutual Releases. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">6.1.</TD><TD STYLE="text-align: justify"><B>Release by Leonite. </B>Effective upon, and only upon, the occurrence of the Closing, Leonite, on behalf
of itself and its past, present and future affiliates, general partners, limited partners, managers, members, officers, directors, employees,
attorneys, agents, representatives, predecessors, successors and assigns (collectively, the &ldquo;Leonite Releasing Parties&rdquo;),
hereby unconditionally, irrevocably, fully and finally releases, acquits and forever discharges the Company and each of its past, present
and future affiliates, subsidiaries, stockholders, officers, directors, employees, attorneys, agents, representatives, predecessors, successors
and assigns (collectively, the &ldquo;Company Released Parties&rdquo;) from any and all claims, counterclaims, demands, actions, causes
of action, suits, proceedings, damages, liabilities, obligations, debts, sums of money, accounts, covenants, contracts, agreements, promises,
judgments, costs and expenses of every kind and nature whatsoever, whether known or unknown, suspected or unsuspected, fixed or contingent,
accrued or unaccrued, liquidated or unliquidated, matured or unmatured, at law or in equity, that any Leonite Releasing Party ever had,
now has or hereafter can, shall or may have against any Company Released Party arising out of, relating to or in connection with any act,
omission, event, occurrence or state of facts existing at or prior to the Closing, including the Transaction Documents, the transactions
contemplated thereby and the Disputes; provided, however, that nothing in this Section 6.1 shall release, waive, discharge or impair (a)
any obligation of any Party arising under this Agreement, including under Sections 5, 7 and 9, or (b) the right of any Party to enforce
this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">6.2.</TD><TD STYLE="text-align: justify"><B>Release by the Company. </B>Effective upon, and only upon, the occurrence of the Closing, the Company,
on behalf of itself and its past, present and future affiliates, subsidiaries, stockholders, officers, directors, employees, attorneys,
agents, representatives, predecessors, successors and assigns (collectively, the &ldquo;Company Releasing Parties&rdquo;), hereby unconditionally,
irrevocably, fully and finally releases, acquits and forever discharges Leonite, Leonite Advisors, LLC and each of their respective past,
present and future affiliates, general partners, limited partners, managers, members, officers, directors, employees, attorneys, agents,
representatives, predecessors, successors and assigns (collectively, the &ldquo;Leonite Released Parties&rdquo;) from any and all claims,
counterclaims, demands, actions, causes of action, suits, proceedings, damages, liabilities, obligations, debts, sums of money, accounts,
covenants, contracts, agreements, promises, judgments, costs and expenses of every kind and nature whatsoever, whether known or unknown,
suspected or unsuspected, fixed or contingent, accrued or unaccrued, liquidated or unliquidated, matured or unmatured, at law or in equity,
that any Company Releasing Party ever had, now has or hereafter can, shall or may have against any Leonite Released Party arising out
of, relating to or in connection with any act, omission, event, occurrence or state of facts existing at or prior to the Closing, including
the negotiation, execution, delivery, funding, performance, administration, amendment or enforcement of the Transaction Documents, the
amount, validity or enforceability of the obligations thereunder, the interest rate, original issue discount, fees and other economic
terms thereof, the securities issued thereunder, the transactions contemplated thereby and the Disputes; provided, however, that nothing
in this Section 6.2 shall release, waive, discharge or impair (a) any obligation of any Party arising under this Agreement or (b) the
right of any Party to enforce this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">6.3.</TD><TD STYLE="text-align: justify"><B>Waiver of Unknown Claims. </B>Each Party acknowledges that it may hereafter discover facts in addition
to, or different from, those which it now knows or believes to be true with respect to the subject matter of the releases set forth in
this Section 6, and each Party, effective upon the Closing, expressly waives, to the fullest extent permitted by law, the provisions,
rights and benefits of any statute, rule, doctrine or common law principle of any jurisdiction that would limit the scope or effectiveness
of a general release with respect to unknown or unsuspected claims, it being the intention of the Parties that the releases set forth
in this Section 6 shall be effective as full and final releases of all released matters notwithstanding the discovery or existence of
any such additional or different facts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">6.4.</TD><TD STYLE="text-align: justify"><B>No Assignment of Claims; Covenant Not to Sue. </B>Each Party represents and warrants that it has not
assigned, transferred, pledged or hypothecated, or purported to assign, transfer, pledge or hypothecate, to any person any claim, demand
or cause of action released pursuant to this Section 6. Each Party covenants, effective upon the Closing, not to commence, prosecute,
maintain, participate in or assist in the prosecution of any action, suit, arbitration or other proceeding against any released party
based in whole or in part upon any claim released pursuant to this Section 6.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify"><B>Indemnification. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">7.1.</TD><TD STYLE="text-align: justify"><B>Indemnification by the Company.</B> From and after the Closing, the Company shall, jointly and severally,
indemnify, defend and hold harmless Leonite, Leonite Advisors, LLC and each of their respective affiliates, general partners, limited
partners, managers, members, officers, directors, employees, attorneys, agents and representatives (collectively, the &ldquo;Leonite Indemnified
Parties&rdquo;) from and against any and all claims, actions, suits, arbitrations, proceedings, investigations, losses, liabilities, damages,
judgments, awards, settlements, fines, penalties, interest, costs and expenses, including reasonable attorneys&rsquo; fees and expenses
and costs of investigation (collectively, &ldquo;Losses&rdquo;), incurred, suffered, sustained or asserted against any Leonite Indemnified
Party arising out of, relating to or in connection with (a) the Transaction Documents or the transaction contemplated thereby, including
the negotiation, execution, delivery, funding, performance, administration, amendment, enforcement or termination thereof; (b) any breach
by the Company of any representation, warranty or covenant contained in this Agreement; (c) the issuance, registration, listing, delivery
or resale of the Settlement Shares, the Registration Statement, any prospectus or prospectus supplement relating thereto, and any actual
or alleged violation of the Securities Act, the Securities Exchange Act of 1934, as amended, or any state securities law in connection
with any of the foregoing, other than Losses arising solely from a resale of Settlement Shares by Leonite effected in violation of applicable
law; and (d) any claim, action or proceeding brought or asserted by any third party, including any stockholder, creditor, trustee, receiver,
examiner or governmental or regulatory authority, relating to any of the matters described in the foregoing clauses (a), (b) or (c); except,
in each case, to the extent that such Losses are finally determined by a court or arbitrator of competent jurisdiction, in a non-appealable
decision, to have resulted primarily from the actual fraud or willful misconduct of such Leonite Indemnified Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">7.2.</TD><TD STYLE="text-align: justify"><B>Indemnification by Leonite.</B> From and after the Closing, Leonite shall indemnify, defend and hold
harmless the Company and each of its affiliates, subsidiaries, stockholders, officers, directors, employees, attorneys, agents and representatives
(collectively, the &ldquo;Company Indemnified Parties&rdquo;) from and against any and all Losses incurred, suffered, sustained or asserted
against any Company Indemnified Party arising out of, relating to or in connection with (a) any breach by Leonite of any representation,
warranty or covenant contained in this Agreement; or (b) any failure by Leonite to perform its obligations under Sections 5.1, 5.2, 5.3
or 5.4 in accordance with their terms; except, in each case, to the extent that such Losses are finally determined by a court or arbitrator
of competent jurisdiction, in a non-appealable decision, to have resulted primarily from the actual fraud or willful misconduct of such
Company Indemnified Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">7.3.</TD><TD STYLE="text-align: justify"><B>Procedures.</B> The applicable indemnified party shall give the indemnifying party reasonably prompt
written notice of any third-party claim for which indemnification is sought, provided that any failure or delay in giving such notice
shall not relieve the indemnifying party of its obligations hereunder except to the extent the indemnifying party is actually and materially
prejudiced thereby. The indemnifying party shall have the right, at its sole expense, to assume the defense of any such third-party claim
upon written notice to the indemnified party within fifteen (15) days after receipt of such notice, provided that the indemnifying party
shall not settle or compromise any such claim without the prior written consent of the indemnified party (not to be unreasonably withheld,
conditioned or delayed) unless such settlement includes an unconditional release of such indemnified party from all liability in respect
thereof and does not include any admission of fault or wrongdoing by, or any restriction upon, such indemnified party. If the indemnifying
party does not timely assume the defense, the indemnified party may defend such claim and seek indemnification hereunder for all reasonable
costs and expenses incurred in connection therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">7.4.</TD><TD STYLE="text-align: justify"><B>Limitations.</B> The aggregate liability of the Company under Section 7.1 (other than with respect
to Losses arising under clause (b) thereof relating to the Settlement Shares) shall not exceed the sum of the Settlement Payment and the
fair market value of the Settlement Shares as of the Closing (determined based on the closing price of the Common Stock on the trading
day immediately preceding the Closing). The obligations of each Party under this Section 7 shall survive the Closing for a period of eighteen
(18) months; provided, however, that claims relating to the issuance of the Settlement Shares under Section 7.1(b) shall survive until
the expiration of the applicable statute of limitations. The indemnification provided in this Section 7 shall be the sole and exclusive
post-Closing remedy of the Parties for any claims arising hereunder, other than claims for fraud or intentional breach.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><B>Representations and Warranties. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">8.1.</TD><TD STYLE="text-align: justify"><B>Mutual Representations. </B>Each Party represents and warrants to the other Party that (a) it is duly
organized, validly existing and in good standing under the laws of its jurisdiction of organization; (b) it has full power and authority
to execute, deliver and perform this Agreement, and the execution, delivery and performance of this Agreement have been duly authorized
by all necessary action on its part; (c) this Agreement has been duly executed and delivered by it and constitutes its legal, valid and
binding obligation, enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency and similar laws
affecting creditors&rsquo; rights generally and general principles of equity; (d) its execution, delivery and performance of this Agreement
do not and will not conflict with, violate or result in a breach of its organizational documents, any agreement or instrument to which
it is a party or by which it is bound, or any law, rule, regulation, order or judgment applicable to it; and (e) it has had the opportunity
to consult with counsel of its choosing in connection with this Agreement and enters into this Agreement voluntarily and without duress.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">8.2.</TD><TD STYLE="text-align: justify"><B>Additional Representations of the Company. </B>The Company represents and warrants to Leonite that
(a) the Registration Statement has been declared effective by the Commission, remains effective, and is available for the issuance of
the Settlement Shares, no stop order suspending its effectiveness has been issued and no proceeding for that purpose has been initiated
or, to the Company&rsquo;s knowledge, threatened by the Commission, and the issuance of the Settlement Shares pursuant to the Registration
Statement will comply with the requirements of Form S-3, including, to the extent applicable, General Instruction I.B.6 thereof; (b) the
Settlement Shares, when issued and delivered in accordance with this Agreement, will be duly authorized, validly issued, fully paid and
nonassessable, free and clear of all liens, claims, encumbrances and rights of third parties, and will be issued in compliance with all
applicable federal and state securities laws and the rules of the NYSE American; (c) no approval of the stockholders of OSTX, and no consent,
approval or authorization of any governmental authority or other person, is required for the execution, delivery and performance of this
Agreement or the issuance of the Settlement Shares, other than the filing of the prospectus supplement contemplated by Section 3, the
listing application contemplated by Section 3 and the disclosure contemplated by Section 9.1; (d) OSTX has a sufficient number of authorized
and unissued shares of Common Stock to permit the issuance of the Settlement Shares; and (e) the Company is not, and after giving effect
to the transactions contemplated hereby will not be, insolvent, and the Company is entering into this Agreement in good faith and for
reasonably equivalent value.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">8.3.</TD><TD STYLE="text-align: justify"><B>Additional Representations of Leonite. </B>Leonite represents and warrants to the Company that (a)
Leonite is the sole legal and beneficial owner of the Note, the Warrant and the Commitment Shares, free and clear of all liens, claims
and encumbrances created by Leonite, and has not sold, assigned, transferred, pledged or hypothecated any interest therein to any person;
(b) Leonite is a sophisticated party with such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of the transactions contemplated by this Agreement; (c) Leonite has not commenced, and is not aware of any basis
to commence, any action, suit, arbitration or other proceeding against any Company Released Party other than the Disputes, and Leonite
has not granted any person any right, interest or claim with respect to any of the foregoing; and (d) the total amount outstanding under
the Note as of the Effective Date, including all principal, accrued interest, original issue discount, fees and other charges, does not
exceed $1,900,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><B>Covenants. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">9.1.</TD><TD STYLE="text-align: justify"><B>Public Disclosure. </B>The Company shall publicly disclose the material terms of this Agreement, by
press release or by the filing of a Current Report on Form 8-K with the Commission, within the time required by applicable law and the
rules of the NYSE American and in any event within four (4) Business Days after the Effective Date, and such disclosure shall include
all material, non-public information, if any, provided or made available to Leonite by or on behalf of the Company at or prior to the
time of such disclosure. From and after such disclosure, the Company shall not provide Leonite with any material, non-public information
without Leonite&rsquo;s prior written consent. Except as required by applicable law, regulation or legal process or the rules of any securities
exchange, neither Party shall issue any press release or public statement concerning this Agreement that disparages the other Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">9.2.</TD><TD STYLE="text-align: justify"><B>Transfer Agent Instructions. </B>Concurrently with the execution of this Agreement, OSTX shall deliver
to the Transfer Agent irrevocable instructions, in form and substance reasonably acceptable to Leonite, directing the Transfer Agent to
(a) issue and deliver the Settlement Shares in accordance with Section 3, (b) upon confirmation of the occurrence of the Closing, cancel
the Commitment Shares in accordance with Section 5.3 and (c) upon confirmation of the occurrence of the Closing, release and cancel the
Reserved Amount (as defined in the TA Letter) and terminate all reservations of shares maintained for the benefit of Leonite under the
TA Letter or any other Transaction Document. The TA Letter shall terminate effective upon the Closing and the Transfer Agent shall thereafter
have no obligation to act upon any instruction of Leonite delivered pursuant thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">9.3.</TD><TD STYLE="text-align: justify"><B>Further Assurances. </B>Each Party shall execute and deliver such further documents and instruments,
and take such further actions, as may be reasonably necessary or appropriate to carry out the purposes and intent of this Agreement, including,
in the case of Leonite following the Closing, the execution and delivery of the releases, terminations and other instruments contemplated
by Section 5.4 at the sole expense of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">9.4.</TD><TD STYLE="text-align: justify"><B>Confidentiality.</B> Except as required by applicable law, regulation, legal process or the rules of
any securities exchange (including the disclosure contemplated by Section 9.1), or with the prior written consent of the other Party,
each Party shall keep confidential and shall not disclose to any person the terms of this Agreement (other than its existence), provided
that each Party may disclose such terms to its affiliates, officers, directors, employees, legal counsel, accountants, financial advisors
and, in the case of Leonite, its limited partners and investors, in each case who have a need to know and who are bound by obligations
of confidentiality no less protective than those set forth herein. The Parties acknowledge that the Company&rsquo;s obligations under
Section 9.1 to publicly disclose the material terms of this Agreement shall not constitute a breach of this Section 9.4.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><B>Failure to Close; Standstill. </B>If the Closing has not occurred on or before the Outside Date for
any reason other than Leonite&rsquo;s willful refusal to accept a delivery properly tendered in accordance with Sections 2 and 3, then:
(i) the Company shall have a period of five (5) Business Days following written notice from Leonite (the &ldquo;Cure Period&rdquo;) within
which to cure such failure; and (ii) if the Closing has not occurred by the end of the Cure Period, then, at Leonite&rsquo;s election,
exercisable by written notice to the Company: (a) this Agreement, other than Sections 7, 10, 11 and 12, shall terminate and be deemed
void ab initio; (b) the releases set forth in Section 6 and the cancellations, satisfactions, terminations and lien releases contemplated
by Section 5 shall be of no force or effect; (c) the Transaction Documents shall continue in full force and effect in accordance with
their terms as if this Agreement had never been executed, and all rights, remedies, claims, defaults and Events of Default of Leonite
thereunder, whether arising before, on or after the Effective Date, are expressly reserved and preserved; (d) any portion of the Settlement
Payment received by Leonite shall be retained by Leonite and applied against amounts outstanding under the Note, without prejudice to
any other right or remedy of Leonite; and (e) any Settlement Shares received by Leonite shall be returned to OSTX for cancellation. From
the Effective Date until the earlier of the Closing and any termination of this Agreement pursuant to this Section 10, Leonite shall not
deliver any notice of conversion under the Note or any notice of exercise under the Warrant. Except as expressly set forth in the immediately
preceding sentence, nothing in this Agreement shall constitute a waiver, forbearance, cure or release of any kind prior to the occurrence
of the Closing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify"><B>No Admission of Liability. </B>This Agreement is entered into in compromise and settlement of the Disputes.
Neither this Agreement, nor any of its terms, nor any act or payment performed or made pursuant to it, shall constitute or be construed
as an admission of any liability, wrongdoing or violation of law by any Party, and each Party expressly denies any such liability, wrongdoing
or violation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><B>Miscellaneous. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.1.</TD><TD STYLE="text-align: justify"><B>Governing Law; Arbitration; Waiver of Jury Trial. </B>This Agreement shall be governed by and construed
in accordance with the laws of the State of Delaware, without regard to principles of conflicts of laws. Any dispute, claim or controversy
arising out of or relating to this Agreement, or the breach, termination, enforcement, interpretation or validity thereof, shall be resolved
in accordance with the dispute resolution provisions set forth in Section 7.3 of the Purchase Agreement, which provisions (including the
arbitration procedures, the designation of Wilmington, Delaware as the seat of arbitration, the carve-out for equitable relief and enforcement
in the state and federal courts residing in Wilmington, Delaware, the prevailing party fee provisions and the notice and service of process
provisions thereof) are incorporated into this Agreement by reference, mutatis mutandis, and shall survive the termination of the Purchase
Agreement solely for purposes of this Agreement. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT
TO A TRIAL BY JURY IN ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.2.</TD><TD STYLE="text-align: justify"><B>Notices. </B>All notices, demands, requests, consents, approvals and other communications required
or permitted under this Agreement shall be given in the manner, and shall be effective at the times, set forth in Section 7.6 of the Purchase
Agreement, which is incorporated into this Agreement by reference, mutatis mutandis, addressed as follows: if to the Company, to OS Therapies
Incorporated, 115 Pullman Crossing Road, Grasonville, MD 21638, Attention: Paul Romness, e-mail: ***, with a copy (which shall not constitute
notice) to ***; and if to Leonite, to Leonite Fund I, LP, 600 East Crescent Avenue, Suite 104, Upper Saddle River, NJ 07458, Attention:
Avi Geller, e-mail: ***, with a copy (which shall not constitute notice) to ***; or, in each case, to such other email address as a Party
may designate by notice given in accordance herewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.3.</TD><TD STYLE="text-align: justify"><B>Entire Agreement. </B>This Agreement, together with the Exhibit hereto, constitutes the entire agreement
of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, negotiations,
discussions and term sheets, whether written or oral, with respect to such subject matter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.4.</TD><TD STYLE="text-align: justify"><B>Amendment; Waiver. </B>No amendment or modification of this Agreement, and no waiver of any provision
hereof or consent to any departure herefrom, shall be effective unless in a writing signed by the Party against whom enforcement is sought.
No failure or delay by a Party in exercising any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise
of any right preclude any other or further exercise thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.5.</TD><TD STYLE="text-align: justify"><B>Assignment; Successors. </B>No Party may assign this Agreement or any of its rights or obligations
hereunder without the prior written consent of the other Party, and any purported assignment in violation of this Section shall be void;
provided that (a) Leonite may designate one or more of its affiliates or accounts to receive delivery of the Settlement Shares and (b)
the Company may assign this Agreement to any successor entity in connection with a merger, consolidation, reorganization or sale of all
or substantially all of its assets without the consent of Leonite, provided that such successor expressly assumes the obligations of the
Company hereunder. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted
assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.6.</TD><TD STYLE="text-align: justify"><B>Third-Party Beneficiaries. </B>The Company Released Parties and the Leonite Released Parties are express
third-party beneficiaries of Section 6, and the Leonite Indemnified Parties and the Company Indemnified Parties are express third-party
beneficiaries of Section 7, in each case with the right to enforce such Sections directly. Except as set forth in the immediately preceding
sentence, nothing in this Agreement, express or implied, is intended to confer upon any person other than the Parties any rights, remedies,
obligations or liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.7.</TD><TD STYLE="text-align: justify"><B>Severability. </B>If any provision of this Agreement is held to be invalid, illegal or unenforceable
in any respect, such provision shall be modified to the minimum extent necessary to render it valid and enforceable, and the validity,
legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.8.</TD><TD STYLE="text-align: justify"><B>Counterparts; Electronic Signatures. </B>This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be
delivered by facsimile, electronic mail (including pdf or any electronic signature complying with applicable law, including DocuSign)
or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and shall be valid
and effective for all purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.9.</TD><TD STYLE="text-align: justify"><B>Specific Performance. </B>Each Party acknowledges and agrees that irreparable damage would occur if
the other Party fails to perform its obligations under this Agreement in accordance with their terms and that monetary damages would not
be an adequate remedy for any such failure. Accordingly, (a) Leonite shall be entitled to specific performance of the Company&rsquo;s
obligations under Sections 2, 3 and 9, and to temporary, preliminary and permanent injunctive relief, in each case without the necessity
of proving actual damages or posting any bond or other security, in addition to any other remedy available at law or in equity; and (b)
the Company shall be entitled to specific performance of Leonite&rsquo;s obligations under Sections 5.1, 5.2, 5.3 and 5.4, and to temporary,
preliminary and permanent injunctive relief, in each case without the necessity of proving actual damages or posting any bond or other
security, in addition to any other remedy available at law or in equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">12.10.</TD><TD STYLE="text-align: justify"><B>Expenses. </B>Except as otherwise expressly provided in this Agreement, each Party shall bear its own
costs, fees and expenses, including attorneys&rsquo; fees, incurred in connection with the negotiation, preparation, execution and performance
of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have executed this Settlement Agreement and Mutual Release as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>COMPANY:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>OS THERAPIES INCORPORATED</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><U STYLE="text-decoration: none">/s/ Paul A. Romness</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Paul A. Romness</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President and Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>OS ANIMAL HEALTH INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><U STYLE="text-decoration: none">/s/ Paul A. Romness</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Paul A. Romness</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Authorized Signatory</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>OS THERAPIES UK LTD</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><U STYLE="text-decoration: none">/s/ Paul A. Romness</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Paul A. Romness</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Authorized Signatory</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>LEONITE:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>LEONITE FUND I, LP</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">By its Manager, Leonite Advisors, LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><U STYLE="text-decoration: none">/s/ Avi Geller</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Avi Geller</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Manager</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ea030084801_ex5-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea030084801_ex5-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  IX# 2(  A$! Q$!_\0
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M[:/KWY?\O_)KG\W/[3T/@K]I[_@JMX@_9B_;#^+GB?X<?L_^!_A'X9UWX,^
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MV^I3:CJ$>B1MY-O:W$K?7=?/3_':2..Q9O"J%XY;F/7%7Q#"486WC9_ ;?\
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M.WCU/Y'_ .-U\_\ _"@H\?\ )8/CI^/Q"F _ _V?S],4G_"@X_\ HL'QT_\
M#AS?_*ZL?8X=[XF__<M7^?\ R\.[ZWFB_P"9/'_P[8#S_P"H?S=O4^@=X]3^
M1_\ C=&\>I_(_P#QNOG[_A0<?_18/CI_X<.;_P"5U'_"@X_^BP?'3_PX<W_R
MNH]CAO\ H)_\MJ__ ,L#ZYFG_0G7_AWP'_S.?0.\>I_(_P#QNC>/4_D?_C=?
M/W_"@X_^BP?'3_PX<W_RNH_X4''_ -%@^.G_ (<.;_Y74>QPW_03_P"6U?\
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M .-U\_?\*#C_ .BP?'3_ ,.'-_\ *ZC_ (4''_T6#XZ?^'#F_P#E=1['#?\
M03_Y;5__ )8'US-/^A.O_#O@/_F<^@=X]3^1_P#C=&\>I_(__&Z^?O\ A0<?
M_18/CI_X<.;_ .5U'_"@X_\ HL'QT_\ #AS?_*ZCV.&_Z"?_ "VK_P#RP/KF
M:?\ 0G7_ (=\!_\ ,Y] [QZG\C_\;HWCU/Y'_P"-U\_?\*#C_P"BP?'3_P .
M'-_\KJ/^%!Q_]%@^.G_APYO_ )74>QPW_03_ .6U?_Y8'US-/^A.O_#O@/\
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M_P"%!1=OC!\=?_#A3#_W'FE_X4#'W^,'QT'U^(4H_G8#W]?K1RTEK]<=]O\
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M62Z\^&UMX(^ 'P"B/_-8/CKUP/\ BX4IS_Y3_P!*/^%!1=/^%P_'7_PX4O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ea030084801_ex5-1img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea030084801_ex5-1img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  F J\# 2(  A$! Q$!_\0
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M (3XC_Y0']JY5_T-,K_\.>6__/ ]3HKRS_A>?P2_Z+%\+/\ PX/A+_Y;T?\
M"\_@E_T6+X6?^'!\)?\ RWH^K8G_ *!L3_X3XC_Y0']JY5_T-,K_ /#GEO\
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M_P#+>CZMB?\ H&Q/_A/B/_E ?VKE7_0TRO\ \.>6_P#SP/4Z*\L_X7G\$O\
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MEO\ \\#U.BO+/^%Y_!+_ *+%\+/_  X/A+_Y;T?\+S^"7_18OA9_X<'PE_\
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MSX%_]%I^$W_AQO!__P N:/\ A?GP+_Z+3\)O_#C>#_\ Y<T?5L3_ - V)_\
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M.BAB\)BN;ZKB\)BN2W/]6Q6%Q/)S7Y>?ZMB<1R<W*^7GY.:SY>:SLM%%%0=
M4444 %%%%  0""" 01@@\@@]01W!KC%\&?#V2>2V3PIX,>YB4/+;KH6B-/&K
M?=>2(6ID16SPS* <\&NQ8,58*=K%2%8C(#$'!QWP><=Z^7/#OA._@'@?2XO
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MPEH,D^F>#])O9(6=);BWTI3?7,I8RRWNI74DY,S.:7M*EF_:U+II)<\];_\
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M$/!\?F,$3S/#^BIO<]$3=:#<Q[*,D]A4G_"!>!?^A+\)_P#A.:/_ /(=>?\
MQC\$:KX[?P5I6GVVG26Z:OKIU*_U6P;4K/1K:\\(:[I\.II:I=6<AU&WN[J
MZ3,DR_9]1-O,^$1C7L5A:FRL;.R-Q/=&TM+>U-U<MON;DV\*1&XN'  >>8IY
MDK8&Z1F.!FASG9/VM2[O=>TJ:6=OY^H+"X5RDOJ>%25K/ZKAM;J[_P"8;H<[
M_P (%X%_Z$OPG_X3FC__ "'1_P (%X%_Z$OPG_X3FC__ "'7644O:5/^?E3_
M ,&5/_DROJF$_P"@3"?^$N&_^9CD_P#A O O_0E^$_\ PG-'_P#D.C_A O O
M_0E^$_\ PG-'_P#D.NLHH]I4_P"?E3_P94_^3#ZIA/\ H$PG_A+AO_F8Y/\
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M )$KIZ*/:5/^?E3_ ,&5/_DP^JX7_H%PW_A-A_\ YG.8_P"$)\&?]"CX8_\
M!!I7_P B4?\ "$^#/^A1\,?^"#2O_D2NGHH]I4_Y^5/_  94_P#DP^JX7_H%
MPW_A-A__ )G.8_X0GP9_T*/AC_P0:5_\B4?\(3X,_P"A1\,?^"#2O_D2NGHH
M]I4_Y^5/_!E3_P"3#ZKA?^@7#?\ A-A__F<YC_A"?!G_ $*/AC_P0:5_\B4?
M\(3X,_Z%'PQ_X(-*_P#D2NGHH]I4_P"?E3_P94_^3#ZKA?\ H%PW_A-A_P#Y
MG.8_X0GP9_T*/AC_ ,$&E?\ R)5<>%/ +$*OAOP@68[5 T?126;SFM]H MLD
M^>K08'/G*T?WP5'7U^-?Q\_9A_:(A^/[Z_\ !?PUI]YX)TOQ!K7C;PKK=QK=
MS9SZ#XB_:-CB\!>.((M,69;6^LO@KXSMK[]I_3X;V"YB?4]<O-,TA+>^='/?
ME]".-JU*5;,%@^6E*I"=:I)4YN-TX.4JT5&3;@TE=RBYM)N%I?,\49E6R#!X
M;%X'AF6?*KC*>%KX? 8:G+%4(5>5K$*E3P-5U*2C"NIR;A"G4CAXSG&%=SI?
MK$GACX?2*KIX>\&NC%E5DTG1&5F1XHF"L+<@E9)H8V )(>6)#AI$!!X8^'Q#
M,/#W@TJCR1N1I.B$))"N^:-C]GPKQ)\\B'#1K\S #FOR2^.W[)/QA^'OC_P0
M_P"S7X!TWQ-\/OA\/"OQ>T'2=4URYT]6^(GA'1O#OPIU+P+<1031QWVE^+(;
M'X6_'&^&J1W-C>^*?@IJ33PR7^MQ31.^/O[&GQ/\'0_#71_@=X1MOB1H&EZ)
MX.^(7Q'M]4UN\T2Y\5?$G]GVUOKV\M9IH+F-KK4_VK="\1ZG\-_&)N9'TXK8
MZ=J6K0W<-KA?1AEN#J?5K9W&*Q4:DH*;C"5)4[RY<2GB[4*DX\JA&<N6523C
MS<L7,^7Q'%N>899OS^'M2I+)JN%H5GAXU*\,;+%.%/VV4N&2\^88:A5]M/$5
M*,.>GA:<:KI^TJJBOUR'@_P,RR.OA;PHR1,ZRL-$T@K&T6?,61A:X1H\'>&(
M*8.X"H8/"_P_N8([JV\.^#KBUE<1Q7,&D:)+!(YD\H)'-';M&[F7]V%5B3)\
M@&[BOA?Q;\*_&6B_L[>'/AK/X4\9^/+O2/&W@7XI_M):=H<44,WQHLO''BO6
M_&7QG\/>$YQJ%F_B*2'Q)<R:AJOA%YK :UX3M+7P?;R7HUA;*3R?7?!]S:77
MBKQQ\%_@5\2_ /P2L?B!^RCK4_PZT[X::WX7UCQ-XO\  GQH@\0_$+Q]X.^#
M8MK36]*LM,\ C1])UV\70=%E\87>F)/%97\>A+JEWA2R^-52Y<PE_%J4X5.:
M"I24)PA34N?&PJQJ8KF=3#15-TW2C>M4I3;C3]'&<3U,'*DI\,T;_4\+B,1A
MU1Q$\73GB*%?$8J5+V/#]?!U<+DWLH83-JD\5#$QQU90P.%QE"$:N)_4-O"?
M@-+B.T?PUX12ZFC>6*V;1M&6XEBC($DD<)MA(\<9(#NJE5) 8C(IR^$/ K^5
ML\+^$W\]&DAVZ)H[><B[2SQ8MCYB*'0LR9 W+D_,,_ WB'0[C6/VL?AQ\7/"
MWPK\<^(KWQOI7A6QUX_$SX-:G80_##PMI^@>.X)O%?@?XJ7$]I<?#?Q!9O?I
MI_BSX5>(+*[?QA-K%M>:=I]G?&34D\I^%7@K]ISX1:#^S)XS\1Z?K/Q,D^'_
M .RM\3](TCX;:1\+KGPOK/A/QUJMA\'K7PMX-\6ZZOBC7'U*]U*]L)]/N;V[
MTS1/L-GH^MZY/&D<%S#"++G*E"2S",*LZ*FJ-6JH3E6Y*[E2C;$S4%&I2C3]
MI7G2C*,I58-J,:<E+BM4\7B*+X7J5\)A\=.C/'X+"2Q%&E@5B,OC2QM13RJA
M.M.KA,94Q/U7+Z&+K4:M.G@Z\(SG/$P_5/\ X0KP7_T*7A?KC_D Z3USC'_'
MIUSQCKGBF'P?X'#!#X6\*!RXC"'1-(#&0H90@4VN2YC5I H&XHI?&T$U^44/
MP9_:L\.?"OQW\ ?'^I^*-;U#QO\ $;X'_%_PY\7_ (/ZSXHU34/#&LZM\>?A
M]=_'2RM]>U[2[2;P]=:;J*:E\5/#FB/977A^Q\+ZOXAT2 7.B>&Y;0=);Z%^
MT%X%^(O_  GWQC\#^)O&,F@?M8>%-7FU_P"$?AK6/%L?C+P)I7[(GBOX<6?Q
M&LO!>C+>:GX>CU3Q1=V%EXG\.QI=6V@>)9[S[#<WNDO87DEO*U[_ "9M0K-.
M?L8TZTN;$148.E.G[2O35JDW4IRA)TZM*5-2E"4*D91PCQC.^'^L<$YC@HR6
M'6.J8K!4W3RRM*K7CBZ&+>&RW$RYL-AXX7%TL116)P>,IXF=*G7I8C"U:57]
M.W\&>"4!9_"GA9%56=F?0M)4*B#+N2;4 *H(+,>%!Y(JN?"WP_ )/ASP< J&
M1B=(T4!4$<4I<G[/P@BFAD+'@1RQ.3MD0G\]?&5C^TKXG^/%O^T=IW@Z_?X+
M>#[R#X.W'P?U9?%-K\0/&OPD\3R6VG?%#Q='\.CITFB:A=2^*K_1?$^D-J%[
M!K,_A+X6FSTZV*^*Y8Y_!/"'[('QV@^.:>'O$?A>WG^"IGTGX+ZCXM?7[RXU
M35O@M\(-5T'XE^&/$5[IDEQ]D?4OBMH&G?#G]G;Q6T,0U2?2_A3=ZA=74EIJ
M"+&Z664W3<Z^;TJ4HX95YPC54Y1J*[JX77$QYL13BX-1AS1G[1*,VX5%%8OB
M[%PQ,*& X&QV,I5<UEEU'$U,&Z%*KA9\L<)G+Y<KJ>QRS$U8XBFZE=4JN'6%
MG4K480KX65;]B)_"?@.U\K[3X:\(V_GS);P>?HVC0^=<29\N"+S+9?,FDVG9
M$F7;!VJ<&FGPKX!6Z6Q/AOP>+UXC.EF='T4730 E3,MN;?S6B# J9 A0$$$Y
MKX]\665EJ_[07A3XC?%3X*^/?'/@?6OAWX#M/@\DO@"[\;?\*<^(\?BGQ#>^
M-)O%?A73!K!\#^(M9L;_ ,"W%OX_FMGL-/LO"^I:7-K^D^0(M5^>]<^&&J36
MGBOPW)\#OB!=_MAZC\;=4\0^&/VCH/"EY)H5MIMQ\29-9\(^.+?XTJ[:9H?@
M#PO\,&T_P]JGPK>_M+^XM],U#P;'X,U--3%]?Y4L!SJ'/C:L'*E3G)J=)PA*
MI.K";;ECX2='!^R2QDE'VRE4@L/1JPM4J=F-XE>&EB/89!A*\*6,Q5"E"=#'
M0Q%>GA</@Z^'A"%+ARM26.SY8N4LAI.HL#4HX:L\RQ^"Q*GA<-^I_P#PA7@L
M<CPEX7ZXS_8.E=<XQG[)USQZYXZUT_3I7X^>*/"O[9,L7Q!U'0K;QHO@[6/C
M?X@_:;TNQ*%?%EG:_"7XL0:+X=^ FFZ"5_M#^R?BKX7\.^#_ (E6.Q3"73Q7
M9RN#K,$1_8('(!Y&0#R"#SZ@\@^H/(KDQV$>&5%O&4L5[3G35*HYNBXQH2Y9
MWG/EE)U*D;+1.@VY/G@>UP[G:S>ICH+(\=DWU54'&>,PL,/#&QJ5LPI>TP[A
MAZ'M*5..&PE52EJXYC!*G!X;$-K1117GGTX4444 %%%% !7C_P"SU\:_"O[2
MGP"^!_[1G@73_$&D^"?C]\'_ (:?&OP=I?BRUTZQ\5:;X5^*G@O1?'7A[3_$
MUCH^JZ]I%GX@L](UVSM]9M=+US6=.M]1CN8;'5=1MDBO)BB@#V"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ostx-20260731.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSayCCaPtypR1yYkxs2t+HXn6/ygokapJhSR61XeWEawO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:OSTX="http://ostherapies.com/20260731" elementFormDefault="qualified" targetNamespace="http://ostherapies.com/20260731">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://ostherapies.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ostx-20260731_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ostx-20260731_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
    <import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
    <import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd" />
    <import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" />
    <import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ostx-20260731_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ostx-20260731_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ostx-20260731.xsd#Cover" roleURI="http://ostherapies.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://ostherapies.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 31,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OS THERAPIES
INCORPORATED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001795091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-5118368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">115 Pullman Crossing Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Grasonville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">297-7793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OSTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ea0300848-8k_ostherapies.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ostherapies.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0300848-8k_ostherapies.htm">ea0300848-8k_ostherapies.htm</File>
    <File>ostx-20260731.xsd</File>
    <File>ostx-20260731_lab.xml</File>
    <File>ostx-20260731_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0300848-8k_ostherapies.htm": {
   "nsprefix": "OSTX",
   "nsuri": "http://ostherapies.com/20260731",
   "dts": {
    "inline": {
     "local": [
      "ea0300848-8k_ostherapies.htm"
     ]
    },
    "schema": {
     "local": [
      "ostx-20260731.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ostx-20260731_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ostx-20260731_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 24
   },
   "report": {
    "R1": {
     "role": "http://ostherapies.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-07-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0300848-8k_ostherapies.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-07-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0300848-8k_ostherapies.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CountryRegion",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Extension",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12gTitle",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-26-086150-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-086150-xbrl.zip
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MCQ/Z1V2"S"J,"7%(E8,9,9.-=3=*-I_9J.=:^/$#%1U&9%I87#_@AQXDVG'
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M^?(T8+8.6C(/^0#9U$.[Y;WL0V,E6#U$\KY74"4B!![XH)(:*D3B&:W)@WR
M<I,9!DSR"L4]:CQ>,DQD5(9Q4^PSGIM#::3Z-!U*QF7E.Z"$(8"N($DL8/KC
MDV],N[$,X2*#[8O0&/T;K'#!2=P-!R"K,!;L:28+[!6W$>4S\6@NO1<4.AC!
M108-KZOYPIYN[>RJC3-C#]$+HHF)OVY&^/.>]_/;) <^>*8G51%/^>>G:F-
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M^2'*H*[Z[=Y-]5-?JOEY.IU$:9<I=7]LXL1:I[M=IUL=\O8IIH 7K.Q'YM;
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M&9UUQN]>O"(7:."/CM@_AI&R/)X36O'(&QK]S\]@JM,IO+LZR+."Q-Y9AHV
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MXUSTW-C5AZE51%NAF:Q73K:H$ &AJ6XMY_)DN=';,1X$7(3LNJ#!.G%<$R]
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M6L0:JJ';.3.],X 59NG8U<F3_. %MZ:5@H^V2!WGCC!M70DC6!J$E7(38=-
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MA8#+H[O[[BP!)8CRD&!)FT<\$RQ%G$I!) ?P0X+@PU/ %N!N<L)SM<+)S:8
MQ&9#/V'@=3'+N+C) =.]W;V=T?.=;MF&UG!E?:H5:XRRX4Y)F^N%-DM?P]!9
MGJ8VPIBE4$O%2Z_7;.!SWB?Q\AGZ[#^NC^?"=K(\F#XFEU$3@:-Z:<0UA>M.
M%&^-AX9H?H]8^/VB\.6FF"@SIE*98*5:B81!>5-G,\&F'#=(W/-8)G0;^?,G
MH0UOVO<ET[.=P*T-IU(#/?Y>TUV]$9FQD#H3&M+*  ]T>991WTJS&E]7H@.
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M/OHZ'U_,I[/9"*499C&FG)'S$>.CGW[\ZU^0_//IN_$8726$QF?H"X_&,_;
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M,J1TJ!!ZZ7E]EX!EZB%&L#FFS"T!=I--"IJ:@$BP&@-HV&OS9TJ]$#&5(Y/
M=,9BLOV%[,!VM71NF0!L-J$P1 %187<&8%&*4:Y&4NX%C#N1K+'8S9.H9ZIH
M"]VB 1EMLF&J H(#L ;04:K1?#;U.9,L\'862U"3AZ1X'KR'$E#O%I8>VTUF
M '% Z'0[! B20:@9Y1.D&8NX>.:UQQVF?",'P-V4Q_ *I2?*+52#FM!$JS,D
M(,"&^ 0P:X1^*)Y)05R]QI-7@%0-7HB[B&-YH-+RG^N$D2.P_5:M6[HZ[#:9
ML@@#(@EV!_!3*C_H#TC%H%L6"C3';VCJL7]HCH="<QPT-,?O@6;QR@.!YN0-
M33WQ#\W)4&A.@H;FY%W0R([W.M9,Y<=;L>"OMH>S0:479-I6K<#L9>'ATO+6
M!XL*4.L9%>(3DWQA=2ON!'])6 0OF2&Y%V  TU9J#&UXZ-@-]O%3+8AUG->Q
MIEB4]WY)M,S/*-,T:1]B"DUXD#2-]0XNA=HG$G<\S3#]=_+<>2)N%WO!PVK8
M"DE#&1XJ-GM]P!0Q2 ;Y.+$N<54W-*RODAGE[EX!MMC:OP)<*PP" INC]BO
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M@DIR^D G42ZS9U9SVY,T<QVAM3XV4W1RV9+:+&U%)V?';XMJ?N]+VS];D:O
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M:P^XM]06W[A?[DVL]LC_4$L! A0#%     @ G:$&77CX@<MC(0  /JD  !P
M             ( !     &5A,#,P,#@T."TX:U]O<W1H97)A<&EE<RYH=&U0
M2P$"% ,4    " "=H09=7['1Y48V  "/'0$ %0              @ &=(0
M96$P,S P.#0X,#%E>#$P+3$N:'1M4$L! A0#%     @ G:$&7:0N 2P=$@
MQ6T  !0              ( !%E@  &5A,#,P,#@T.# Q97@T+3$N:'1M4$L!
M A0#%     @ G:$&74I)< B-"0  \R0  !0              ( !96H  &5A
M,#,P,#@T.# Q97@U+3$N:'1M4$L! A0#%     @ G:$&7063KH<J P  ZPL
M !$              ( !)'0  &]S='@M,C R-C W,S$N>'-D4$L! A0#%
M  @ G:$&7=?P#?3]"@  ?X8  !4              ( !?7<  &]S='@M,C R
M-C W,S%?;&%B+GAM;%!+ 0(4 Q0    ( )VA!EV(OH]Z60<  -I7   5
M          "  :V"  !O<W1X+3(P,C8P-S,Q7W!R92YX;6Q02P4&      <
,!P#6 0  .8H

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea0300848-8k_ostherapies_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ostx-20260731.xsd" xlink:type="simple"/>
    <context id="AsOf2026-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2026-07-31</startDate>
            <endDate>2026-07-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-07-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-07-31" id="Fact000004">0001795091</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-07-31" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-07-31" id="Fact000010">2026-07-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-07-31" id="Fact000011">OS THERAPIES INCORPORATED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-07-31" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-07-31" id="Fact000013">001-42195</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-07-31" id="Fact000014">82-5118368</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-07-31" id="Fact000015">115 Pullman Crossing Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-07-31" id="Fact000016">Suite 103</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-07-31" id="Fact000017">Grasonville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-07-31" id="Fact000018">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-07-31" id="Fact000019">21638</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-07-31" id="Fact000020">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-07-31" id="Fact000021">297-7793</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-07-31" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-07-31" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-07-31" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-07-31" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-07-31" id="Fact000026">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-07-31" id="Fact000027">OSTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-07-31" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-07-31" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-07-31" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
